Patent · US Active

Inhibitors of HCV NS5A

US9120779B2 · kind B2 · utility

2Cited by

2References

18Claims

0Family size

Assignee

Presidio Pharmaceuticals, Inc. · US

Inventors

Leping Li · San Francisco, US
Min Zhong · Palo Alto, US

Key dates

Filing date	Dec 2, 2009
Grant date	Sep 1, 2015
Priority date	—
Expiry date	Jun 2, 2031

Classification

Technology area (CPC C)Chemistry; Metallurgy
CPC primaryC07D417/14
WIPO fieldOrganic fine chemistry
WIPO sectorChemistry

Abstract

The invention relates to non-macrocyclic, non-peptidic, substituted heterocyclic compounds useful for inhibiting hepatitis C virus (“HCV”) replication, particularly functions of the non-structural 5A (“NS5A”) protein of HCV.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.